

Chemicals/Finland, August 16, 2024 Company update

Solid earnings recovery

Exel's $\Omega 2$ was encouraging as EBIT recovered significantly after a challenging period of missing demand. We believe EBIT could climb towards EUR 8m in the next year or so.

Revenue and gross margin improved, costs mostly controlled Exel Q2 revenue grew 5% y/y to EUR 26.6m vs our EUR 24.7m estimate as activity rebounded in most industries except Energy where the company is only beginning to ramp up volumes in the new Indian factory. Order backlog was up 31% y/y at the end of Q2, although prolonged macroeconomic uncertainties mean volumes may not increase much more q/q in H2 even if they are likely to remain a lot higher y/y. Gross margin gained 500bps y/y due to factors such as improved capacity utilization, product mix and pricing. Staff costs had one-offs (e.g. restructuring costs), but despite this the EUR 1.4m adj. EBIT was clearly above our EUR 0.3m estimate. Exel's operating leverage means EBIT could improve a lot more q/q over the following quarters in a high demand scenario, but we don't estimate further big gains in the short-term.

We estimate H2'24 EBIT margins at around 6%

The Industrial BU still has modest volumes (17% of H1 revenue vs the 40% long-term target) as e.g. the new factory in India is yet to ramp up its capacity and wind power activity is only starting to recover. Exel could revise its revenue guidance upwards later this year but its factory network review is not yet done, and it might mean more production restructuring and hence have an impact on revenue. Even if FY '24 top line may not grow faster than the 7% rate we estimate we believe industrial activity is more likely than not to continue its recovery towards next year. Exel is thus likely to see further earnings gains in the next 12 months. We estimate only modest q/q EBIT improvement in Q3 to EUR 1.5m.

Valuation not demanding assuming 7% EBIT next year

We believe Exel could achieve an annual EBIT run-rate of EUR 6m quite soon, and continued volume growth should be able to lift it further up close to EUR 8m already next year. Exel is hence valued at a still rather high 14x EV/EBIT on our FY '24 estimates due to a challenging Q1, which might mean annual EBIT stays around EUR 4m, however continued stable development would soon bring the multiple below 10x and it would be around 7x already next year. We retain our EUR 0.40 TP; our rating is now BUY (HOLD).



■ BUY □ HOLD ■ SELL

KEY FIGL	JRES									
	Sales EURm	EBIT EURm	EBIT %	FCF EURm	EPS EUR	P/E (x)	EV/Sales (x)	EV/EBIT (x)	FCF yield %	DPS EUR
2022	137.0	3.0	2.2%	7.8	0.04	30.1	0.7	31.4	12.0	0.05
2023	96.8	-4.9	-5.0%	-0.8	-0.19	-3.2	0.6	-12.6	-2.7	0.00
2024E	103.5	3.9	3.8%	11.8	0.02	15.1	0.5	13.9	34.3	0.00
2025E	111.7	7.8	7.0%	1.9	0.05	6.9	0.5	6.7	5.6	0.01
2026E	117.3	9.4	8.0%	7.7	0.06	5.1	0.4	4.9	22.3	0.01
Market cap	, EURm		34 G	earing 2024E,	%		98.9 CAGR E	EPS 2023-26	i, %	0.0
Net debt 2	024E, EURm		20 Pr	ice/book 2024	E		1.7 CAGR s	ales 2023-2	6, %	6.6
Enterprise	value, EURm		54 Di	vidend yield 2	024E, %		0.0 ROE 20	24E, %		12.1
Total asset	s 2024E, EURn	n	78 Ta	x rate 2024E,	%			5.2		
Goodwill 2	024E, EURm		13 Ec	uity ratio 202	4E, %	25.7 PEG, P/E 24/CAGR				0.3



Chemicals/Finland, August 16, 2024 Company update

-170 %

-31 %

Estimates and valuation

Exel Composites	Q1'23	Q2'23	Q3'23	Q4'23	2023	Q1'24	Q2'24	Q3'24e	Q4'24e	2024e
Buildings and infrastructure	5.7	5.0	4.2	3.7	18.6	4.8	5.5	5.6	4.2	20.1
Industrial	5.5	3.4	3.0	3.5	15.4	3.4	4.2	4.2	4.4	16.1
Energy	6.2	5.4	5.3	4.9	21.8	5.3	4.5	5.7	6.0	21.4
Transportation	4.4	4.0	3.3	4.7	16.3	3.9	5.0	4.5	6.0	19.5
Other	7.1	7.6	4.7	5.3	24.7	6.0	7.5	6.6	6.5	26.5
Revenue	28.8	25.4	20.5	22.1	96.8	23.4	26.6	26.5	27.0	103.5
y/y change, %	-16 %	-33 %	-39 %	-29 %	-29 %	-19 %	5 %	29 %	22 %	7 %
Adjusted EBIT	0.0	0.1	-1.2	-1.3	-2.4	-0.6	1.4	1.5	1.8	4.1
EBIT	-0.3	-0.2	-0.7	-3.7	-4.9	-0.6	1.2			3.9
-margin, %	0.0 %	0.3 %	-5.9 %	-5.9 %	-2.5 %	-2.4 %	5.2 %	<i>5.7 %</i>	6.7 %	4.0 %
-margin (reported), %	-1.0 %	-1.0 %	-3.2 %	-16.7 %	-5.0 %	-2.4 %	4.4 %			3.8 %

Source: Evli Research

	MCAP		EV/EBITDA			EV/EBIT			EBIT-%		
EXEL COMPOSITES PEER GROUP	MEUR	23	24	25	23	24	25	23	24	25	
Hexagon Composites	600	16.4x	17.8x	11.8x	33.5x	35.7x	17.8x	4.2 %	5.1 %	9.0 %	
Hexcel	4686	19.6x	15.6x	13.2x	31.5x	23.8x	19.0x	12.1 %	13.1 %	14.9 %	
Avient	3844	10.8x	11.0x	10.1x	17.4x	17.3x	15.2x	10.0 %	10.5 %	11.4 %	
SGL Carbon	740	6.9x	5.1x	4.2x	8.4x	8.3x	6.2x	10.1 %	9.3 %	11.6 %	
TPI Composites	168		143.8x	7.8x			13.6x	-10.9 %	-3.5 %	3.4 %	
Gurit Holding	206	12.7x	6.1x	5.1x	22.2x	9.1x	7.2x	4.3 %	6.2 %	7.5 %	
Peer Group Average	1707	13.3x	33.2x	8.7x	22.6x	18.9x	13.2x	5.0 %	6.8 %	9.6 %	
Peer Group Median	670	12.7x	13.3x	9.0x	22.2x	17.3x	14.4x	7.1 %	7.7 %	10.2 %	
Exel Composites (Evli est.)	34	16.0x	5.5x	3.7x	-12.6x	13.9x	6.7x	-5.0 %	3.8 %	7.0 %	

-157%

Exel Composites prem./disc. to peer median

Source FactSet, Evli Research

VALUATION RESULTS	BASE CASE DETAILS	VALUATION ASSUMPTIONS	ASSUMPTIONS FOR WACC	
Current share price	0.32 PV of Free Cash Flow	74 Long-term growth, %	1.5 Risk-free interest rate, %	2.25
DCF share value	1.17 PV of Horizon value	82 WACC, %	8.5 Market risk premium, %	5.8
Share price potential, %	262.4 Unconsolidated equity	0 Spread, %	0.5 Debt risk premium, %	3.3
Maximum value	1.3 Marketable securities	11 Minimum WACC, %	8.0 Equity beta coefficient	1.00
Minimum value	1.1 Debt - dividend	-43 Maximum WACC, %	9.0 Target debt ratio, %	10
Horizon value, %	52.5 Value of stock	125 Nr of shares, Mn	106.7 Effective tax rate, %	21

DCF valuation, EURm	2023	2024E	2025E	2026E	2027E	2028E	2029E	2030E	2031E	2032E	2033E	Horizon
Net sales	97	103	112	117	120	122	124	127	130	132	134	136
Sales growth, %	-29.3	6.9	8.0	5.0	2.0	2.0	2.0	2.0	2.0	2.0	1.5	1.5
Operating income (EBIT)	-5	4	8	9	13	12	14	15	15	15	15	15
Operating income margin, %	-5.0	3.8	7.0	8.0	10.5	10.0	11.0	11.5	11.5	11.0	11.0	11.0
+ Depreciation+amort.	9	6	6	7	6	6	5	5	5	5	5	
EBITDA	4	10	14	17	19	18	19	20	20	19	20	
- Paid taxes	0	-1	-2	-2	-2	-2	-2	-2	-2	-2	-2	
- Change in NWC	3	8	-5	-2	0	0	0	0	0	0	0	
NWC / Sales, %	11.7	2.7	6.8	7.8	7.8	7.8	7.8	7.8	7.8	7.8	7.8	
+ Change in other liabs	0	0	0	0	0	0	0	0	0	0	0	
- Operative CAPEX	-3	-4	-4	-4	-4	-4	-4	-5	-5	- 5	-5	
opCAPEX / Sales, %	4.0	4.7	4.2	4.0	3.7	3.7	3.7	3.7	3.7	3.7	3.7	
- Acquisitions	0	0	0	0	0	0	0	0	0	0	0	
+ Divestments	0	0	0	0	0	0	0	0	0	0	0	
- Other items	0	0	0	0	0	0	0	0	0	0	0	
= FCFF	4	14	3	9	12	11	12	12	12	12	12	177
= Discounted FCFF		13	3	8	9	8	8	7	7	6	6	82
= DFCF min WACC		13	3	8	9	8	8	8	7	6	6	92
= DFCF max WACC		13	3	8	9	8	8	7	7	6	5	74

INTERIM	FIGURES
---------	---------

EVLI ESTIMATES, EURm	2023Q1	2023Q2	2023Q3	2023Q4	2023	2024Q1	2024Q2	2024Q3E	2024Q4E	2024E	2025E	2026E
Net sales	28.8	25.4	20.5	22.1	96.8	23.4	26.6	26.5	27.0	103.5	111.7	117.3
EBITDA	1.5	1.4	1.3	-0.4	3.8	0.9	2.6	3.0	3.3	9.8	14.2	16.6
EBITDA margin (%)	5.3	5.7	6.1	-1.7	4.0	3.8	9.8	11.3	12.2	9.5	12.7	14.2
EBIT	-0.3	-0.2	-0.7	-3.7	-4.9	-0.6	1.2	1.5	1.8	3.9	7.8	9.4
EBIT margin (%)	-1.0	-1.0	-3.2	-16.7	-5.0	-2.4	4.4	5.7	6.7	3.8	7.0	8.0
Net financial items	-1.2	-0.4	0.2	-2.0	-3.4	0.0	-0.4	-0.4	-0.4	-1.2	-1.2	-1.3
Pre-tax profit	-1.5	-0.7	-0.4	-5.7	-8.3	-0.6	8.0	1.1	1.4	2.7	6.6	8.1
Tax	-0.6	-0.2	-0.2	0.0	-1.1	0.0	-0.3	-0.1	-0.1	-0.5	-1.6	-1.3
Tax rate (%)	-43.8	-36.3	-48.2	0.8	-12.8	0.0	32.2	9.1	7.1	16.6	24.2	16.6
Net profit	-2.1	-0.9	-0.6	-5.6	-9.3	-0.6	0.5	1.0	1.3	2.3	5.0	6.7
EPS	-0.04	-0.02	-0.01	-0.11	-0.19	-0.01	0.01	0.01	0.01	0.02	0.05	0.06
EPS adjusted (diluted no. of shares)	-0.04	-0.02	-0.01	-0.11	-0.19	-0.01	0.01	0.01	0.01	0.02	0.05	0.06
Dividend per share	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.01	0.01
SALES, EURm												
Exel Composites	28.8	25.4	20.5	22.1	96.8	23.4	26.6	26.5	27.0	103.5	111.7	117.3
Total	28.8	25.4	20.5	22.1	96.8	23.4	26.6	26.5	27.0	103.5	111.7	117.3
SALES GROWTH, Y/Y %												
Exel Composites	-15.7	-33.3	-39.2	-28.8	-29.3	-18.9	4.7	29.0	22.3	6.9	8.0	5.0
Total	-15.7	-33.3	-39.2	-28.8	-29.3	-18.9	4.7	29.0	22.3	6.9	8.0	5.0
EBIT, EURm											· ·	
Exel Composites	-0.3	-0.2	-0.7	-3.7	-4.9	-0.6	1.2	1.5	1.8	3.9	7.8	9.4
Total	-0.3	-0.2	-0.7	-3.7	-4.9	-0.6	1.2	1.5	1.8	3.9	7.8	9.4
EBIT margin, %						_						
Exel Composites	-1.0	-1.0	-3.2	-16.7	-5.0	-2.4	4.4	5.7	6.7	3.8	7.0	8.0
Total	-1.0	-1.0	-3.2	-16.7	-5.0	-2.4	4.4	5.7	6.7	3.8	7.0	8.0

INCOME STATEMENT, EURm	2019	2020	2021	2022	2023	2024E	2025E	2026E
Sales	103.8	108.6	134.4	137.0	96.8	103.5	111.7	117.3
Sales growth (%)	7.5	4.6	23.7	2.0	-29.3	6.9	8.0	5.0
EBITDA	10.7	15.3	11.9	10.1	3.8	9.8	14.2	16.6
EBITDA margin (%)	10.3	14.1	8.9	7.4	4.0	9.5	12.7	14.2
Depreciation	-5.6	-5.8	-8.2	-7.1	-8.7	-5.9	-6.4	-7.2
EBITA	5.1	9.4	3.7	3.0	-4.9	3.9	7.8	9.4
Goodwill amortization / writedown	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
EBIT	5.1	9.4	3.7	3.0	-4.9	3.9	7.8	9.4
EBIT margin (%)	4.9	8.7	2.8	2.2	-5.0	3.8	7.0	8.0
Reported EBIT	5.1	9.4	3.7	3.0	-4.9	3.9	7.8	9.4
EBIT margin (reported) (%)	4.9	8.7	2.8	2.2	-5.0	3.8	7.0	8.0
Net financials	-1.2	-2.3	0.4	0.6	-3.4	-1.2	-1.2	-1.3
Pre-tax profit	3.9	7.1	4.2	3.6	-8.3	2.7	6.6	8.1
Taxes	-1.5	-1.7	-2.5	-1.5	-1.1	-0.5	-1.6	-1.3
Minority shares	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Net profit	2.4	5.4	1.7	2.1	-9.3	2.3	5.0	6.7
Cash NRIs	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Non-cash NRIs	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
BALANCE SHEET, EURm	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Assets								
Fixed assets	23	30	34	31	25	24	22	20
Goodwill	13	13	13	13	13	13	13	13
Right of use assets	5	3	3	2	1	1	2	2
Inventory	17	16	24	23	17	13	17	18
Receivables	20	21	26	24	18	14	17	19
Liquid funds	7	12	16	17	11	12	13	14
Total assets	85	97	118	113	85	78	84	85
Liabilities								
Shareholder's equity	26	29	31	30	18	20	25	31
Minority interest	0	0	0	0	0	0	0	0
Convertibles	0	0	0	0	0	0	0	0
Lease liabilities	4	2	2	1	0	1	2	2
Deferred taxes	0	0	0	1	0	0	0	0
Interest bearing debt	32	40	50	46	42	30	30	24
Non-interest bearing current liabilities	21	24	32	26	22	23	25	27
Other interest-free debt	2	2	3	9	3	3	3	3
Total liabilities	85	97	118	113	85	78	84	85
CASH FLOW, EURm						,,,		
+ EBITDA	11	15	12	10	4	10	14	17
- Net financial items	-1	-2	0	1	-3	-1	-1	-1
- Taxes	-2	-2	-3	-1	0	0	-2	-1
- Increase in Net Working Capital	1	3	-5	3	3	8	-5	-2
+/- Other	0	0	0	0	0	0	0	0
= Cash flow from operations	8	13	5	13	3	17	7	12
- Capex	-8	-13	-11	-5	-4	-5	-5	-5
- Acquisitions	-0	-13	-11	-5 0	0	-5	-5	-5 0
+ Divestments	0	0	0	0	0	0	0	0
= Free cash flow	1	0	-6	8	-1	12	2	8
+/- New issues/buybacks	0	-1	-6 3	-1	-1 -1	0	0	0
- Paid dividend	-2		-2	-1 -2		0	0	
- Paid dividend +/- Other	-2 3	-2 7	-2 9	-2 -3	-2 -2	-11	0	-1 -6
		5	4	-3 2	-2 -6		2	-6 1
Change in cash	2	Э	4	2	-0	1	2	Į

KEY FIGURES	2020	2021	2022	2023	2024E	2025E	2026E
M-cap	88	94	64	30	34	34	34
Net debt (excl. convertibles)	30	36	30	32	20	18	11
Enterprise value	118	131	94	61	54	52	46
Sales	109	134	137	97	103	112	117
EBITDA	15	12	10	4	10	14	17
EBIT	9	4	3	-5	4	8	9
Pre-tax	7	4	4	-8	3	7	8
Earnings	5	2	2	-9	2	5	7
Equity book value (excl. minorities)	29	31	30	18	20	25	31
Valuation multiples							
EV/sales	1.1	1.0	0.7	0.6	0.5	0.5	0.4
EV/EBITDA	7.7	10.9	9.3	16.0	5.5	3.7	2.7
EV/EBITA	12.5	34.9	31.4	-12.6	13.9	6.7	4.9
EV/EBIT	12.5	34.9	31.4	-12.6	13.9	6.7	4.9
EV/OCF	8.8	27.2	7.4	19.6	3.3	7.9	3.7
EV/FCFF	52.9	-26.0	12.5	17.5	4.0	15.7	4.9
P/FCFE	754.8	-64.5	35.0	-157.6	2.9	17.8	4.5
P/E	16.4	57.0	30.1	-3.2	15.1	6.9	5.1
P/B	3.1	3.0	2.1	1.7	1.7	1.4	1.1
Target EV/EBITDA	0.0	0.0	0.0	0.0	6.4	4.3	3.2
Target EV/EBIT	0.0	0.0	0.0	0.0	16.0	7.7	5.7
Target EV/FCF	0.0	0.0	0.0	0.0	5.3	31.3	7.0
Target P/B	0.0	0.0	0.0	0.0	2.1	1.7	1.4
Target P/E	0.0	0.0	0.0	0.0	18.7	8.5	6.3
Per share measures							
Number of shares	50,132	50,132	50,132	50,132	106,686	106,686	106,686
Number of shares (diluted)	50,132	50,132	50,132	50,132	106,686	106,686	106,686
EPS	0.11	0.03	0.04	-0.19	0.02	0.05	0.06
Operating cash flow per share	0.27	0.10	0.25	0.06	0.16	0.06	0.12
Free cash flow per share	0.01	-0.12	0.15	-0.02	0.11	0.02	0.07
Book value per share	0.57	0.62	0.61	0.35	0.19	0.23	0.29
Dividend per share	0.05	0.05	0.05	0.00	0.00	0.01	0.01
Dividend payout ratio, %	44.3	143.7	110.9	0.0	0.0	21.2	15.8
Dividend yield, %	2.7	2.5	3.7	0.0	0.0	3.1	3.1
FCF yield, %	0.6	-6.5	12.0	-2.7	34.3	5.6	22.3
Efficiency measures							
ROE	19.5	5.5	7.0	-38.7	12.1	22.3	24.2
ROCE		5.5	7.0	-30.7			440
	14.4				5.2	12.7	14.6
Financial ratios		5.1	4.0	-8.8	5.2	12.7	14.6
					5.2 13.0	12.7	15.5
Financial ratios	14.4	5.1	4.0	-8.8			
Financial ratios Inventories as % of sales	14.4	5.1 17.8	4.0 17.1	-8.8 17.4	13.0	15.0	15.5
Financial ratios Inventories as % of sales Receivables as % of sales	14.4 14.9 19.2	5.1 17.8 19.6	17.1 17.8	-8.8 17.4 18.1	13.0 13.5	15.0 15.5	15.5 16.0
Financial ratios Inventories as % of sales Receivables as % of sales Non-interest bearing liabilities as % of sales	14.4 14.9 19.2 22.0	5.1 17.8 19.6 23.8	4.0 17.1 17.8 19.1	-8.8 17.4 18.1 22.7	13.0 13.5 22.7	15.0 15.5 22.7	15.5 16.0 22.7
Financial ratios Inventories as % of sales Receivables as % of sales Non-interest bearing liabilities as % of sales NWC/sales, %	14.4 14.9 19.2 22.0 11.2	5.1 17.8 19.6 23.8 12.7	17.1 17.8 19.1 10.3	-8.8 17.4 18.1 22.7 11.7	13.0 13.5 22.7 2.7	15.0 15.5 22.7 6.8	15.5 16.0 22.7 7.8
Financial ratios Inventories as % of sales Receivables as % of sales Non-interest bearing liabilities as % of sales NWC/sales, % Operative CAPEX/sales, % CAPEX/sales (incl. acquisitions), %	14.4 14.9 19.2 22.0 11.2 11.9	5.1 17.8 19.6 23.8 12.7 8.2	17.1 17.8 19.1 10.3 3.6	-8.8 17.4 18.1 22.7 11.7 4.0	13.0 13.5 22.7 2.7 4.7 4.7	15.0 15.5 22.7 6.8 4.2 4.2	15.5 16.0 22.7 7.8 4.0
Financial ratios Inventories as % of sales Receivables as % of sales Non-interest bearing liabilities as % of sales NWC/sales, % Operative CAPEX/sales, % CAPEX/sales (incl. acquisitions), % FCFF/EBITDA	14.4 14.9 19.2 22.0 11.2 11.9	5.1 17.8 19.6 23.8 12.7 8.2 8.2	17.1 17.8 19.1 10.3 3.6 3.6	-8.8 17.4 18.1 22.7 11.7 4.0 4.0	13.0 13.5 22.7 2.7 4.7	15.0 15.5 22.7 6.8 4.2	15.5 16.0 22.7 7.8 4.0 4.0
Financial ratios Inventories as % of sales Receivables as % of sales Non-interest bearing liabilities as % of sales NWC/sales, % Operative CAPEX/sales, % CAPEX/sales (incl. acquisitions), %	14.4 14.9 19.2 22.0 11.2 11.9 11.9 0.1	5.1 17.8 19.6 23.8 12.7 8.2 8.2 -0.4	17.1 17.8 19.1 10.3 3.6 3.6 0.7	-8.8 17.4 18.1 22.7 11.7 4.0 4.0 0.9	13.0 13.5 22.7 2.7 4.7 4.7	15.0 15.5 22.7 6.8 4.2 4.2	15.5 16.0 22.7 7.8 4.0 4.0 0.6
Financial ratios Inventories as % of sales Receivables as % of sales Non-interest bearing liabilities as % of sales NWC/sales, % Operative CAPEX/sales, % CAPEX/sales (incl. acquisitions), % FCFF/EBITDA Net debt/EBITDA, book-weighted	14.4 14.9 19.2 22.0 11.2 11.9 11.9 0.1 2.0	5.1 17.8 19.6 23.8 12.7 8.2 8.2 -0.4 3.0	17.1 17.8 19.1 10.3 3.6 3.6 0.7 2.9	-8.8 17.4 18.1 22.7 11.7 4.0 4.0 0.9 8.2	13.0 13.5 22.7 2.7 4.7 4.7 1.4 2.0	15.0 15.5 22.7 6.8 4.2 4.2 0.2	15.5 16.0 22.7 7.8 4.0 4.0 0.6

EVLI EQUITY RESEARCH

EXEL COMPOSITES

Chemicals/Finland, August 16, 2024 Company update

COMPANY DESCRIPTION: Exel Composites manufactures composites profiles for various demanding, mainly industrial end-use, applications. Exel's customer base includes companies operating in industries such as wind energy, transportation and telecommunications. Exel Composites is one of the largest manufacturers of pultruded composites profiles globally and currently operates eight manufacturing plants on three continents.

INVESTMENT CASE: Our positive view is based on good long-term composites demand outlook, coupled with the fact that Exel Composites' current manufacturing footprint could support annual revenue in the EUR 150m ballpark i.e. there's still plenty of room to improve delivery volumes. Exel's rather high fixed cost base translates to meaningful operating leverage, and thus higher revenues should lead to improving operating margins. The company is also progressing well with its cost savings program. Operating profit could further significantly improve if good execution continues. Recently the wind energy sector has provided great lift for volumes; other attractive applications include e.g. transportation industry profiles.

OWNERSHIP STRUCTURE	SHARES	EURm	0/0
Erikoissijoitusrahasto Aktia Mikro Markka	6,866,856	2.218	6.4%
OP-Finland Small Firms Fund	5,446,457	1.759	5.1%
Elo Mutual Pension Insurance Company	5,123,275	1.655	4.8%
Danske Invest Finnish Equity Fund	4,707,032	1.520	4.4%
Phoebus Fund	3,780,000	1.221	3.5%
Säästöpankki Pienyhtiöt	3,080,659	0.995	2.9%
Proprius partners micro finland (non-ucits)	2,930,971	0.947	2.7%
Nelimarkka Heikki Antero	1,913,463	0.618	1.8%
Veritas Pension Insurance Company Ltd.	1,890,009	0.610	1.8%
Suutarinen Timo	1,440,000	0.465	1.3%
Ten largest	37,178,722	12.009	35%
Residual	69,507,278	22.451	65%
Total	106,686,000	34.460	100%

EARNINGS CALENDAR	
October 31, 2024	Q3 report
OTHER EVENTS	

COMPANY	MISCELLANEOUS

CEO: Paul Sohlberg CFO: Mikko Rummukainen

IR: Lilli Riikonen

Mäkituvantie 5 01510 Vantaa Tel: +358 20 7541 200

Chemicals/Finland, August 16, 2024 Company update

DEFINITIONS

P/E	EPS
Price per share Earnings per share	Profit before extraord. items and taxes- income taxes + minority interest Number of shares
Lattilitys per stiate	Number of snares
P/BV	DPS
Price per share	Dividend for the financial period per share
Shareholders' equity + taxed provisions per share	
Madestana	OCT (On each flow)
Market cap	OCF (Operating cash flow)
Price per share * Number of shares	EBITDA – Net financial items – Taxes – Increase in working capital – Cash NRIs ± Other adjustments
	,
EV (Enterprise value)	FCF (Free cash flow)
Maylet on a not dobt a minority interest at maylet value	
Market cap + net debt + minority interest at market value – share of associated companies at market value	Operating cash flow – operative CAPEX – acquisitions + divestments
EV/Sales	FCF yield, %
Evisaics	Tel yield, 70
Enterprise value	Free cash flow
Sales	Market cap
EV/EBITDA	Operative CAPEX/sales
EVILORIOR	Operative of a Expansion
Enterprise value	Capital expenditure – divestments – acquisitions
Earnings before interest, tax, depreciation and amortization	Sales
EV/EBIT	Net working capital
Enterprise value Operating profit	Current assets – current liabilities
Operating profit	
Net debt	Capital employed/Share
Interest bearing debt – financial assets	Total assets – non-interest bearing debt
interest dearing deot – financial assets	Number of shares
Total assets	Gearing
Balance sheet total	Net debt
	Equity
Divided 06	Dob+/Caujty, 06
Div yield, %	Debt/Equity, %
Dividend per share	Interest bearing debt
Price per share	Shareholders' equity + minority interest + taxed provisions
Payout ratio, %	Equity ratio, %
,	
Total dividends	Shareholders' equity + minority interest + taxed provisions
Earnings before extraordinary items and taxes – income taxes + minority interest	Total assets – interest-free loans
ROCE, %	CAGR, %
Profit before extraordinary items + interest expenses+ other financial costs	Cumulative annual growth rate = Average growth per year
Balance sheet total – non-interest bearing debt (average)	
Profit before extraordinary items + interest expenses+ other financial costs Balance sheet total – non-interest bearing debt (average)	Cumulative annual growth rate = Average growth per year

EVLI EQUITY RESEARCH

EXEL COMPOSITES

ROE, %		
	Profit before extraordinary items and taxes – income taxes Shareholder's equity + minority interest + taxed provisions (average)	

Chemicals/Finland, August 16, 2024 Company update

Important Disclosures


Evli Research Partners Plc ("ERP") uses 12-month target prices. Target prices are defined by utilizing analytical techniques based on financial theory including (but not limited to) discounted cash flow analysis and comparative valuation. The selection of valuation methods depends on different circumstances. Target prices may be altered on the basis of new information coming to light in the underlying company or changes in interest rates, changes in foreign exchange rates, other securities prices or market indices or outlook for the aforementioned factors or other factors that may change the conditions of financial markets. Recommendations and changes by analysts are available at <u>Analysts' recommendations and ratings revisions</u>.

Investment recommendations are defined as follows:

Target price compared to share price Recommendation

< -10 % SELL -10 - (+10) % HOLD > 10 % BUY

ERP's investment recommendation of the analyzed company is updated at least 2 times per year.



The graph above shows the distribution of ERP's recommendations of companies under coverage in 11th of May 2020. If recommendation is not given, it is not mentioned here.

Name(s) of the analyst(s): Ilvonen

This research report has been prepared by Evli Research Partners Plc ("ERP" or "Evli Research"). ERP is a subsidiary of Evli Plc. Production of the investment recommendation has been concluded on [16.8.2024, 8:45]. This report has been published on [16.8.2024, 9:00].

None of the analysts contributing to this report, persons under their guardianship or corporations under their control have a position in the shares of the company or related securities.

The date and time for any price of financial instruments mentioned in the recommendation refer to the previous trading day's closing price(s) unless otherwise stated in the report.

Each analyst responsible for the content of this report assures that the expressed views accurately reflect the personal views of each analyst on the covered companies and securities. Each analyst assures that (s)he has not been, nor are or will be, receiving direct or indirect compensation related to the specific recommendations or views contained in this report.

Companies in the Evli Group, affiliates or staff of companies in the Evli Group, may perform services for, solicit business from, hold long or short positions in, or otherwise be interested in the investments (including derivatives) of any company mentioned in the publication or report.

Neither ERP nor any company within the Evli Group have managed or co-managed a public offering of the company's securities during the last 12 months prior to, received compensation for investment banking services from the company during the last 12 months prior to the publication of the research report.

ERP has signed an agreement with the issuer of the financial instruments mentioned in the recommendation, which includes production of research reports. This assignment has a limited economic and financial impact on ERP and/or Evli. Under the assignment ERP performs services including, but not limited to, arranging investor meetings or –events, investor relations communication advisory and production of research material.

ERP or another company within the Evli Group does not have an agreement with the company to perform market making or liquidity providing services.

EVLI EQUITY RESEARCH

EXEL COMPOSITES

Chemicals/Finland, August 16, 2024 Company update

For the prevention and avoidance of conflicts of interests with respect to this report, there is an information barrier (Chinese wall) between Investment Research and Corporate Finance units concerning unpublished investment banking services to the company. The remuneration of the analyst(s) is not tied directly or indirectly to investment banking transactions or other services performed by Evli Plc or any company within Evli Group.

This report has not been disclosed to the company prior to its dissemination.

This report is provided and intended for informational purposes only and may not be used or considered under any circumstances as an offer to sell or buy any securities or as advice to trade any securities.

This report is based on sources ERP considers to be correct and reliable. The sources include information providers Reuters and Bloomberg, stock-exchange releases from the companies and other company news, Statistics Finland and articles in newspapers and magazines. However, ERP does not guarantee the materialization, correctness, accuracy or completeness of the information, opinions, estimates or forecasts expressed or implied in the report. In addition, circumstantial changes may have an influence on opinions and estimates presented in this report. The opinions and estimates presented are valid at the moment of their publication and they can be changed without a separate announcement. Neither ERP nor any company within the Evli Group are responsible for amending, correcting or updating any information, opinions or estimates contained in this report. Neither ERP nor any company within the Evli Group will compensate any direct or consequential loss caused by or derived from the use of the information represented in this publication.

All information published in this report is for the original recipient's private and internal use only. ERP reserves all rights to the report. No part of this publication may be reproduced or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, or stored in any retrieval system of any nature, without the written permission of ERP.

This report or its copy may not be published or distributed in Australia, Canada, Hong Kong, Japan, New Zealand, Singapore or South Africa. The publication or distribution of this report in certain other jurisdictions may also be restricted by law. Persons into whose possession this report comes are required to inform themselves about and to observe any such restrictions.

Evli Plc is not registered as a broker-dealer with the U. S. Securities and Exchange Commission ("SEC"), and it and its analysts are not subject to SEC rules on securities analysts' certification as to the currency of their views reflected in the research report. Evli is not a member of the Financial Industry Regulatory Authority ("FINRA"). It and its securities analysts are not subject to FINRA's rules on Communications with the Public and Research Analysts and Research Reports and the attendant requirements for fairness, balance and disclosure of potential conflicts of interest. This research report is only being offered in U.S. by Auerbach Grayson & Company, LLC (Auerbach Grayson) to Major U.S. Institutional Investors and is not available to, and should not be used by, any U.S. person or entity that is not a Major U.S. Institutional Investor. Auerbach Grayson is a broker-dealer registered with the U.S. Securities and Exchange Commission and is a member of the FINRA. U.S. entities seeking more information about any of the issuers or securities discussed in this report should contact Auerbach Grayson. The securities of non-U.S. issuers may not be registered with or subject to SEC reporting and other requirements.

ERP is not a supervised entity but its parent company Evli Plc is supervised by the Finnish Financial Supervision Authority.

Chemicals/Finland, August 16, 2024 Company update

Contact information
SALES, TRADING AND RESEARCH

Joachim Dannberg Ari Laine +358 9 4766 9123 +358 9 4766 9115 +358 9 4766 9130 Kimmo Lilja

Trading

Lauri Vehkaluoto (Head) Pasi Väisänen +358 9 4766 9120 +358 9 4766 9120 +358 9 4766 9120 +358 9 4766 9120 Antti Kässi Miika Ronkanen

Structured Investments

Heikki Savijoki +358 9 4766 9726

Equity Research

Atte Jortikka +358 40 054 3725 Joonas Ilvonen Jerker Salokivi +358 44 430 9071 +358 9 4766 9149

Evli Investment Solutions

+358 9 4766 9205 Johannes Asuja



EVLI PLC Aleksanterinkatu 19 A P.O. Box 1081 P.O. Box 1081
FIN-00101 Helsinki, FINLAND
Phone +358 9 476 690
Internet www.evli.com
E-mail firstname.lastname@evli.com

EVLI PLC, STOCKHOLMSFILIAL Regeringsgatan 67 P.O. Box 16354 SE-103 26 Stockholm Sverige stockholm@evli.com Tel +46 (0)8 407 8000